INMUNE BIO ($NASDAQ:INMB) reported total revenue of USD 0.1 million for its fiscal year 2023 second quarter ending June 30th 2023, representing a year-over-year increase of 150%. Net income for the same period was USD -6.5 million, a slight decrease compared to the previous year’s figure of -6.8 million. This announcement was made on August 7 2023.
With an intermediate health score of 4/10 considering its cashflows and debt, investors interested in such a company may be looking for potential future growth or a target which may be able to pay off debt and fund future operations. INMUNE BIO is strong in asset and growth and weak in dividend and profitability. This may make it attractive to investors looking for companies with potential growth and opportunities, but that have not yet achieved the same level of success as larger companies. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Inmune Bio. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Inmune Bio. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Inmune Bio. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Inmune Bio are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
In the biopharmaceutical industry, there is intense competition to develop innovative therapies. INmune Bio Inc is a company that is constantly striving to create new and better treatments for patients. Its main competitors are Galectin Therapeutics Inc, Sigilon Therapeutics Inc, and Compugen Ltd. All of these companies are working hard to develop treatments that will improve the lives of patients.
– Galectin Therapeutics Inc ($NASDAQ:GALT)
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company, which focuses on developing therapies to treat fibrotic disease and cancer. The company’s lead product candidate, GR-MD-02, is a galactoarabinan polysaccharide that is being developed as a potential treatment for non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and pancreatitis. Galectin Therapeutics Inc was founded in 2000 and is headquartered in Norcross, GA.
– Sigilon Therapeutics Inc ($NASDAQ:SGTX)
Sigilon Therapeutics Inc is a clinical stage biopharmaceutical company developing novel therapeutic approaches for the treatment of rare diseases. The company’s lead product candidate is a cell-based therapy for the treatment of hemophilia A. Sigilon Therapeutics Inc has a market cap of 15.55M as of 2022, a Return on Equity of -110.08%.
The company’s focus on developing cell-based therapies for rare diseases puts it in a good position to take advantage of the growing market for these treatments. However, its high ROE indicates that it is still in the early stages of development and faces significant risks.
Compugen Ltd is a biotechnology company that discovers and develops therapeutic and diagnostic proteins to treat and diagnose a variety of diseases. The company has a market capitalization of $74.27 million and a negative return on equity of 35.26%. Compugen’s products are used to treat conditions such as cancer, inflammatory diseases, and infections. The company’s pipeline includes several therapeutic and diagnostic candidates in clinical and preclinical development.
INMUNE BIO reported total revenue of USD 0.1 million for the second quarter ending June 30 2023, representing a 150.0% year-over-year increase. Although net income for the same period was USD -6.5 million, a slight improvement from last year’s loss of USD -6.8 million, investors may want to be cautious when considering investing in INMUNE BIO. The company has yet to return a profit, and its future performance will be the ultimate determinant of potential returns for investors.